Skip to main content
TipRanks
Go Ultimate75% OFF

Agios Pharma (AGIO) AI Stock Analysis

700 Followers
AGIO

Agios Pharma

(NASDAQ:AGIO)

Select Model
Rating:55Neutral
Price Target:$34.00â–²(12.77% Upside)
Action:reiterated
Date:11/06/26

AGIO scores moderately due to a strong balance sheet, accelerating revenue, and a notably constructive earnings-call outlook (launch traction, pipeline progress, expense discipline, and clear profitability targets). The score is held back by substantial ongoing losses and heavy negative free cash flow, alongside weak price trend signals (below key moving averages with negative MACD).

Positive Factors
Rapid commercial revenue growthThe sharp increase in quarterly revenue shows meaningful commercial traction for AQVESME and expanding product adoption. If prescription growth and persistence continue, the launch can create a stronger recurring revenue base and improve operating leverage over the next several quarters.
Negative Factors
Persistent losses and cash burnLarge ongoing losses and negative free cash flow mean the business is not yet self-funding despite accelerating revenue. Continued cash consumption could reduce financial flexibility over time and may require operating improvement or additional financing before profitability is reached.

Agios Pharma (AGIO) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%AGIO+22.71%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.80B
Dividend Yield
―
Average Volume (3M)
1.06M
Price to Earnings (P/E)
-4.8
Beta (1Y)
1.64
Revenue Growth
214.44%
EPS Growth
9.13%
Country
US
Employees
540
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Agios Pharma Business Overview & Revenue Model

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a med...

How the Company Makes Money

Agios makes money primarily through (1) net product revenue from sales of its approved medicines and (2) collaboration and license-related income (such as upfront payments, milestone payments, and royalties) from partners, when applicable. Product re...

Agios Pharma Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-3.92%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Agios reported record revenue, rapid AQVESME launch adoption, 75% six-month persistence, international growth, a strong cash position, readiness for a potential sickle cell launch, and encouraging pipeline data. The main challenges were the three-month FDA review extension and uncertainty around a potential REMS, along with higher SG&A, a continuing net loss, and a planned one-time headcount reduction charge.

Positive Updates

Record Third-Quarter Revenue
Agios delivered record total net revenue of $55.4 million in the third quarter, more than 4x the $12.9 million reported in the third quarter of 2025. The company generated more total revenue in a single quarter than it generated in all of 2025.

Negative Updates

Sickle Cell Review Timeline Extended
The FDA requested additional information regarding whether a risk evaluation and mitigation strategy, or REMS, is necessary for mitapivat in sickle cell disease. The agency classified Agios' response as a major amendment, procedurally extending the review timeline by three months to February 1, 2027.

Company Guidance

Agios said full year operating expenses are expected to remain approximately flat versus 2025 excluding the $25 million upfront payment associated with the cevidoplenib in licensing and an approximately $11 million onetime expense associated with the headcount reduction to be recognized in the fourth quarter; over the course of 2026, R&D headcount will have reduced by more than 35 percent compared with 2025, or more than 100 roles, with associated cost savings expected to be realized in 2027, and the company is targeting non GAAP profitability in 2028, including the potential launch of sickle cell in 2027. Agios plans to initiate a phase 3 program for AG-236 in polycythemia vera by year end, a phase 3 trial for cevidoplenib in immune thrombocytopenia in the first half of 28, and expects Phase 1b proof-of-concept data for AG-181 before the end of the year; it also expects Phase 2/3 initiation for AG-236 by the end of this year, with every-6-month dosing as the goal of Phase 2, and described 177 prescriptions as probably the more run rate for AQVESME as it continues to penetrate the thalassemia markets.

Agios Pharma Financial Statement Overview

Summary

Mixed fundamentals: strong revenue acceleration and very high gross margin (~92%), supported by a low-leverage balance sheet (debt-to-equity ~0.03). However, profitability is deeply negative (TTM net margin ~-265%) and cash burn is heavy (TTM operating cash flow about -$331.7M; free cash flow about -$336.0M), which meaningfully offsets the strengths.

Income Statement

34Negative

Balance Sheet

78Positive

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue140.84M54.03M36.50M26.82M14.24M0
Gross Profit129.50M42.51M32.33M17.32M12.54M-18.78M
EBITDA-378.33M-408.62M723.62M-345.46M-223.24M-347.27M
Net Income-372.90M-412.78M673.73M-352.09M-231.80M1.60B
Balance Sheet
Total Assets1.06B1.30B1.66B937.12M1.24B1.44B
Cash, Cash Equivalents and Short-Term Investments630.01M854.42M893.71M776.93M783.12M1.02B
Total Debt26.53M40.21M56.99M72.00M85.66M97.09M
Total Liabilities84.70M104.11M122.24M126.10M137.90M145.76M
Stockholders Equity979.34M1.19B1.54B811.02M1.10B1.29B
Cash Flow
Free Cash Flow-335.97M-377.29M-391.53M-297.06M-314.36M-413.06M
Operating Cash Flow-331.68M-372.98M-389.84M-296.06M-309.48M-407.32M
Investing Cash Flow355.56M377.18M363.44M239.57M243.26M1.25B
Financing Cash Flow11.97M8.68M14.44M5.43M2.35M-765.77M

Agios Pharma Technical Analysis

Technical Analysis SentimentNegative
Last Price30.15

Price Trends

50DMA33.03Negative
100DMA34.34Negative
200DMA31.86Negative

Market Momentum

MACD-0.73Positive
RSI42.03Neutral
STOCH64.84Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGIO, the sentiment is Negative. The current price of 30.15 is below the 20-day moving average (MA) of 33.42, below the 50-day MA of 33.03, and below the 200-day MA of 31.86, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 42.03 is Neutral, neither overbought nor oversold. The STOCH value of 64.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AGIO.

Agios Pharma Risk Analysis

Agios Pharma disclosed 54 risk factors in its most recent earnings report. Agios Pharma reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development program and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.Q4, 2025
2.Changes in and uncertainty surrounding U.S. trade policy could have a material adverse impact on our business, financial condition and results of operations.Q4, 2025
3.We conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.Q4, 2024

Agios Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AGIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NRIXNRIX61Neutral$1.61B5.9249.34%―738.76%―
AGIOAGIO55Neutral$1.80B-4.84-34.63%―214.44%9.13%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IOVAIOVA51Neutral$3.49B-14.24-29.71%―51.31%56.78%
NTLANTLA49Neutral$1.38B-2.91-64.73%―-8.07%21.55%
RARERARE48Neutral$1.62B-3.08213.22%―15.76%12.63%
BEAMBEAM42Neutral$2.17B-20.91-9.69%―163.27%77.49%

* Healthcare Sector Average

Performance Comparison

0%200%400%AGIORAREIOVANTLABEAMNRIXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AGIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AGIOAgios Pharmaceuticals30.157.8134.96%
RAREUltragenyx Pharmaceutical, Inc.15.90-15.96-50.09%
IOVAIovance Biotherapeutics7.555.29234.07%
NTLAIntellia Therapeutics Inc9.861.6219.66%
BEAMBeam Therapeutics, Inc.20.94-0.04-0.19%
NRIXNurix Therapeutics, Inc.14.730.402.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026